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Introduction
The growth of lightweight piglets is usually slower
and less eff icient than that of heavier littermates.
According to Wigmore and Stickland (1983), it is
possible that slower growth may result from continuous
competitive disadvantage, and not necessarily be
caused by reduced numbers of secondary muscle fibers,
when compared to heavier littermates.
It is known that the uterine environment may affect
antenatal development of secondary muscle f ibers
mainly due to the influence of nutritional and hormonal
factors, able to stimulate increased fiber formation, thus
affecting post-natal growth (Dwyer et al., 1993). These
factors may affect not only the number of fibers, but
birth weight and growth rate of animals as well (Handel
and Stickland, 1987; Dwyer and Stickland, 1991).
Low glucose or amino acid uptakes by the fetoplacental
unit resulting from nutritional def iciencies will
promote increased fetal catabolism (Simmons et al.,
1978; Battaglia and Meschia, 1978, cited by Gluckman,
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Abstract
The effects of the use of ractopamine (20 ppm per sow and day) in sows were evaluated during three different pregnancy
stages (T1: 25 to 50; T2: 50 to 80; T3: 25 to 80 days of gestation, and T4: control-no ractopamine), assessing possible
effects on reproduction, litter performance up to weaning, blood parameters, as well as on some of the biochemistry
parameters at 20, 40, 60, 80, and 100 days of pregnancy. Forty sows were included in the trial for the evaluation of
reproductive measures and litter performance. As to blood counts, a total of 10 sows were used. The use of 20 ppm of
ractopamine during the three pregnancy stages had no effects on reproductive measures, litter performance or blood values,
when compared to the control. However, total cholesterol, high density lipids and triglyceride values were different (P < 0.05)
between treated and control sows (71.80 mg dl-1 vs 65.04 mg dl-1; 42.30 mg dl-1 vs 37.00 mg dl-1, and 59.40 mg dl-1 vs 53.40
mg dl-1, respectively), indicating the action of the drug on protein and lipid metabolism. This experiment demonstrated
that the use of ractopamine in pregnant sows did not affect the performance of the sows and the progeny until weaning.
Additional key words: beta-adrenergic, blood parameters, gestation, lipid profile, swine.
Resumen
Efectos de la utilización de ractopamina en cerdas gestantes sobre parámetros reproductivos y sanguíneos
Se analizaron los efectos de la utilización de ractopamina (20 ppm) en cerdas durante tres diferentes fases de la ges-
tación (T1: entre los días 25 y 50 de la gestación; T2: entre 50 y 80; T3: desde el día 25 hasta el 80; T4: control, sin
ractopamina) sobre los resultados reproductivos, el desarrollo de los lechones hasta el destete, los valores sanguíneos
y bioquímicos a los 20, 40, 60, 80 y 100 días de gestación. Se utilizaron 40 cerdas para evaluar los índices repro-
ductivos y el desarrollo de los lechones y 10 para los análisis de sangre. La utilización de ractopamina en los tres pe-
ríodos de gestación no tuvo efectos significativos sobre los resultados reproductivos, el peso de los lechones al naci-
miento y al destete y las variables sanguíneas, comparado con el grupo control. Sin embargo, los niveles de coleste-
rol total, de los lípidos de alta densidad y de los triglicéridos fueron diferentes (P < 0,05) en cerdas tratadas y no
tratadas. Tales resultados indican la acción de la ractopamina sobre el metabolismo lipídico y proteico (71,80 vs 65,04
mg dl-1; 42,30 vs 37,00 mg dl-1 y 59,40 vs 53,40 mg dl-1). Este trabajo demostró que la utilización de ractopamina en
cerdas gestantes no afecta a los resultados productivos de las madres y de los lechones hasta el destete.
Palabras clave adicionales: beta adrenérgico, cerdas, gestación, perfil lipídico, valores sanguíneos.
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1986), and reduce the endocrine stimulus for cell
replication. In addition, the development of the placen-
ta is also affected (Pilistine et al., 1984, cited by
Gluckman, 1986).
Maternal glucose crossing the placenta is the
primary nutrient for fetal production. Thus, glucose is
considered to be an important fetal growth-regulating
factor (Bassett et al., 1990). In addition, high blood
sugar levels promote the release of fetal IGF (Insulin-
like Growth Factor) that has a direct effect on myoblast
proliferation and differentiation.
From this, it can be concluded that fetal deve-
lopment could be influenced, and consequently, birth
weight and post-natal growth could also be changed
(Hegarty and Allen, 1978). There is a positive
correlation between antenatal and post-natal develop-
ment (Campbell and Dunkin, 1982).
During the stage when muscle f ibers undergo
hyperplasia, the number of membrane beta-adrenergic
receptors is increased (Parent et al., 1980; Schonberg
et al., 1980). Thus, the use of a beta-adrenergic agonist
(ractopamine) during this stage could optimize fetal
muscle f iber replication through adenosine cyclic
monophosphate (cAMP) modulation. In turn, deve-
lopment of the piglets could be improved during the
post-natal life stages.
Administration of the beta-adrenergic agonist
cimaterol to rats has resulted in increased functional
activity and size of mammary gland cells (Choi et al.,
1992), suggesting that the use of ractopamine in pregnant
sows could improve milk production, allowing for a
better nutrition of the progeny (Kim et al., 1994).
Kim et al. (1994) treated sows with salbutamol
(beta-adrenergic agonist) during three different stages
of pregnancy and did not see improvements in birth
weights. However, when the authors quantified muscle
f ibers, the results favored the treated groups,
suggesting that the number of muscle f ibers is not
directly related to birth weight.
The goal of this trial was to evaluate the use of
ractopamine in pregnant sows and to assess possible
effects on reproductive measures, on the performance
of the litter up to weaning and on some blood parameters.
Material and Methods
The trial was conducted at the gestation and farro-
wing units of a commercial 450-sow farm located in
Rolândia, Parana State, Brazil.
Forty hybrid (Large White × Landrace) 3-4-parity
pregnant sows were used. During pregnancy, the breeders
were housed individually. After farrowing, the piglets
were identified to allow follow-up according to their
mothers’ treatments. Piglets were maintained with the
sows up to weaning (at 21 days of age).
The trial was started at artif icial insemination of
the sows. The semen used for insemination was
obtained from hybrid boars with the same genetic
background.
At 20 days of pregnancy ten sows were randomly
assigned to each of 4 treatment groups. Treatments
were administered via the feed as follows: T1: 20 ppm
ractopamine from 25 to 50 days of pregnancy (pre-
hyperplasic stage); T2: 20 ppm ractopamine from 50
to 80 days of pregnancy (hyperplasic stage); T3: 20
ppm ractopamine from 25 to 80 days of pregnancy
(pre-hyperplasic stage + hyperplasic stage); T4: control
(no ractopamine).
During gestation, routine management was maintained,
and the sows were fed 1.8 kg of feed per day up to 80
days of pregnancy. From day 80 on, the sows were fed
on average 2.8 kg of feed per day until farrowing.
Pregnancy and pre-lactation feeds for all the four
treatment groups were formulated according to the
NRC (1998) (Table 1).
During pregnancy, blood samples were collected
from two groups of 5 sows at 20, 40, 60, 80, and 100
days. Five sows belonged to the group receiving racto-
pamine from 25 to 80 days of pregnancy, and the other
5 sows belonged to the control group (without ractopa-
mine). Blood tests were conducted at the Clinical
Pathology Laboratory of the Londrina State University
and in the Pathology Laboratory of the North of
Parana.
From farrowing to weaning, sows were fed lactation
feed ad libitum, formulated according to the NRC
guidelines (1998).
The following measures were used to assess the
reproductive performance of the sows and litter per-
formance: total number of piglets born, number of
piglets born alive, number of stillborns, litter weight
at farrowing, number of weaned piglets and weaning
weights. Blood collected from the sows was tested for
the following parameters: total lipids (TL), total cho-
lesterol (TC), low density lipids (LDL), high density
lipids (HDL), triglycerides (TG), blood glucose (BG),
blood urea nitrogen (BUN), creatinine (CR), total
serum protein level (TP), hemoglobin (HB), hematocrit
(HM), leukocyte count (LC), lymphocyte count (LF),
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neutrophil count (NC), monocyte count (MC), rod
count (RC), and eosinophil count (EC).
For reproductive and litter performance measures,
the experimental design was completely randomized,
with 4 treatments and 10 replicates per treatment.
For blood parameters, the experimental design was
completely randomized using a 2 × 5 factorial arran-
gement of treatments (2 treatments and 5 blood
collection periods), with 5 replicates, each sow repre-
senting a treatment repetition.
Variance analysis and Tukey’s test were used in the
GLM procedure as outlined by SAS (1999) to evaluate
the results obtained in the trial. Blood parameters were
tested by regression analysis and Student’s t Test
according to the sample collection schedules.
Results
Table 2 shows the results related to the total number
of piglets born, piglets born alive and weights at birth
and at weaning. No differences were detected among
treatments (P > 0.05).
Table 3 shows the results obtained for blood counts.
Total cholesterol (TC), HDL and triglycerides (TG) were
signif icantly different (P < 0.05) among treatments.
There were no significant differences seen for the other
measures (P > 0.05).
Table 4 shows the results of blood cell counts:
hemoglobin (HB), hematocrit (HM), leukocyte (LC),
lymphocyte (LF), neutrophil (NC), monocyte (MC),
rod (RC) and eosinophil (EC) counts. There were no
significant differences (P > 0.05) among treatments. It
can, therefore, be concluded that the drug had no
harmful effects on any of the blood parameters evaluated.
When blood parameters were analyzed by sampling
period for both treatments, it was noted that total lipids
showed no response to regression analysis in ractopa-
mine-treated animals, but in untreated controls (Fig. 1)
there was a linear effect (Y = 160.02 + 0.689X; R2 =
0.70; P < 0.01).
Low density lipids (LDL) were positive for re-
gression analysis in both treatments (Fig. 2), with a
cubic effect in ractopamine-treated sows (Y = 59.6451
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Table 1. Percentage and calculated composition of the ex-
perimental feeds fed during pregnancy (0 to 80 days of preg-
nancy), pre-lactation (81 days of pregnancy to farrowing)




Corn 54.70 64.18 54.98
Wheat bran 30.60 6.00 —
Soybean meal 11.00 23.80 31.00
Vegetable oil — 2.04 5.02
Limestone 1.35 1.08 0.92
Dicalcium phosphate 1.35 1.90 2.08
Salt 0.50 0.50 0.50
Sugar — — 5.00
Premix1 0.40 0.40 —
Premix2 — — 0.40
Premix3 0.10 0.10 0.10
Total 100.00 100.00 100.00
Calculated values4
Crude protein (%) 14.07 16.89 18.49
Metab. En. (kcal kg-1) 2,865 3,170 3,375
Crude fiber (%) 5.06 3.90 3.59
Ether extract (%) 3.43 5.09 7.54
Calcium (%) 0.95 0.95 0.94
Total phosphorus(%) 0.75 0.70 0.69
Lysine (%) 0.63 0.88 1.03
1 Vitamin and mineral supplement per kg of product: vit. A,
1,250,000 IU; vit.D3, 250,000 IU; vit. E, 8,750 IU; vit. K3, 
150 mg; vit. B1, 125 mg; vit. B2, 1,125 mg; vit. B6, 150 mg;
vit. B12, 4,500 mcg; folic acid, 400 mg; calcium pantothenate,
3,250 mg; niacin, 3,750 mg; biotin, 50 mg; choline, 70,000 mg;
iron, 12,250 mg; copper, 5,250 mg; manganese, 8,750; zinc,
26,250 mg; iodine, 350 mg; selenium, 75 mg; antioxidants,
1,000 mg. 2 Vitamin and mineral supplement per kg of product:
vit. A, 1,000,000 IU; vit.D3, 250,000 IU; vit. E, 8,750 IU; vit.
K3, 163 mg; vit. B1, 125 mg; vit. B2, 1,125 mg; vit. B6, 150 mg;
vit. B12, 4,500 mcg; folic acid, 400 mg; calcium pantothenate,
3,000 mg; niacin, 3,500 mg; biotin, 45 mg; choline, 70,000 mg;
iron, 10,500 mg; copper, 4,500 mg; manganese, 7,500; zinc,
22,500 mg; iodine, 300 mg; selenium, 75 mg; antioxidants,
1,000 mg. 3 Mineral supplement  per kg of product: Fe, 60,000 mg;
Cu, 120,000 mg; Zn, 60,000 mg. 4 As-fed basis.
Table 2. Treatment of pregnant sows with ractopamine at
different gestational ages: effects on total number of piglets







25 to 50 days 11.81 11.24 1.67 ± 0.14 6.08 ± 0.51
50 to 80 days 11.00 10.80 1.60 ± 0.29 5.74 ± 1.03
25 to 80 days 13.11 11.13 1.52 ± 0.20 5.42 ± 1.06
Controls 11.32 10.39 1.55 ± 0.22 5.74 ± 0.48
CV (%) 11.61 12.21 13.50 13.37
There was no signif icant difference between treatments
(P > 0.05).
– 2.75594X + 0.0529631X2 – 0.000304656X3; R2 =
0.97; P < 0.01) and a linear effect in untreated controls
(Y = 27.36 – 0.166X; R2 = 0.85; P < 0.01).
High density lipids (HDL) showed a positive
response to regression analysis for both treatments
(Fig. 3), with a cubic effect in ractopamine-treated
sows (Y = –22.6946 + 3.96957X – 0.06769X2 +
0.000346316X3; R2 = 0.99; P < 0.05) and a linear effect
in untreated controls (Y = 30.28+0.112X; R2 = 0.41; 
P < 0.05).
Triglycerides showed no response to regression
analysis in ractopamine-treated animals, but in untreated
controls (Fig. 4) there was a linear effect (Y = 30.48 +
0.382X; R2 = 0.83; P < 0.01).
BUN showed a positive response to regression
analysis for both treatments (Fig. 5). For ractopa-
mine-treated sows, the equation is Y = 50.395 –
1.48241X + 0.0139571X2 (R2 = 0.80; P < 0.01), and 
for the untreated group, Y = 51.6705 – 1.64148X +
0.0164076X2 (R2 = 0.91; P < 0.01). Although no inter-
action was observed between the treatments and days,
according to the Student’s t test only the means at 100
days were different (P < 0.05) between the control and
the test group.
Total protein levels were also positive for regression
analysis in both groups (Fig. 6). For ractopamine-
treated sows, the equation is Y = 4.509 + 0.0641089X
– 0.000493303X2 (R2 = 0.90; P < 0.01), and for 
the untreated controls, Y = 4.4328 + 0.0650859X –
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Table 3. Serum biochemistry results: total lipids (TL), total cholesterol (TC), low density lipids (LDL), high density lipids
(HDL), triglycerides (TG), blood glucose (BG), blood urea nitrogen (BUN), creatinine (CR), total protein (TP). Samples
obtained from ractopamine-treated (25 to 80 days of pregnancy) and untreated sows
Treatment
TL TC LDL HDL TG BG BUN CR TP
(mg dl–1) (mg dl–1) (mg dl–1) (mg dl–1) (mg dl–1) (mg dl–1) (mg dl–1) (mg dl–1) (g dl–1)
Ractopamine 223.05a ± 53.87 71.80a ± 12.11 17.65a ± 7.74 42.30a ± 10.01 59.40a ± 25.03 71.79a ± 11.68 22.86a ± 12.83 2.11a ± 0.41 6.19a ± 0.54
Controls 201.36a ± 32.86 65.04b ± 8.19 17.40a ± 6.91 37.00b ± 7.57 53.40b ± 17.33 67.79a ± 14.19 25.38a ± 17.03 2.17a ± 0.28 6.11a ± 0.61
Averages in the same column with different superscripts are significantly different (P < 0.05).
Table 4. Blood counts results: hemoglobin (HB), hematocrit (HM), leukocyte (LC), lymphocyte (LF), neutrophil (NC), 
monocyte (MC), rod (RC) and eosinophil (EC) counts. Samples obtained from ractopamine-treated (25 to 80 days of 
pregnancy) and untreated sows
Treatment
HB HM LC LF NT MN BT ES
(g dl–1) (%) (number µl–1) (%) (%) (%) (%) (%)
Ractopamine 14.04 ± 1.66 37.35 ± 3.54 12,555 ± 3,953 52.75 ± 15.38 43.30 ± 15.17 0.75 ± 1.16 0.10 ± 0.31 3.05 ± 2.39
Controls 13.93 ± 1.88 37.32 ± 3.82 14,264 ± 4,485 56.68 ± 16.22 39.44 ± 16.45 0.52 ± 0.96 0.28 ± 0.68 3.00 ± 2.61
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Figure 1. Total serum lipid levels (TL) (mg dl-1) in untreated













Figure 2. Serum low density lipid levels (LDL) (mg dl-1) by
sampling day, for ractopamine-treated (25 to 80 days of preg-
nancy) and untreated sows.
0.000505716X2 (R2 = 0.90; P < 0.01). By using the
Student’s t test, the means of the treatments for each
period evaluated (20, 40, 60, 80 and 100) were similar
(P > 0.05).
Discussion
Ractopamine did not affect piglet performance up
to weaning or the reproductive performance of the
treated sows. These results agree with those obtained
by Kim et al. (1994), who used salbutamol, a beta-
adrenergic agonist in pregnant sows and did not see
any effect on birth and weaning weights in piglets
produced by treated sows compared to the controls.
Although birth weights were not improved by
ractopamine, this does not necessarily mean that the
number of muscle fibers remained unchanged. According
to Handel and Stickland (1988), birth weight is not a
good indicator of total number of muscle fibers. In pigs
with a high number of muscle fibers, these fibers are
of smaller diameter than in animals with fewer fibers
(Dwyer et al., 1993). Higher numbers of muscle fibers
only became evident when pigs reached 70 days old or
weighed 25 kg, compared to animals with a lower
number of fibers (Dwyer et al., 1993). Thus, growth
rate up to 25 kg of bodyweight is independent of the
number of fibers.
If we analyze only birth and weaning weights, the
absence of signif icant differences shows that when
sows are treated in periods other than the final third of
pregnancy, there is no effect on piglet growth. Based
on weaning weights, it can be hypothesized that the
treatments had no effect on milk production, in contrast
to the hypothesis of Kim et al. (1994), and findings by
















Figure 3. Serum high density lipid levels (HDL) (mg dl-1) by
sampling day, for ractopamine-treated (25 to 80 days of preg-









20 40 60 80 100
Days
TG
Figure 4. Serum triglyceride levels (TG) (mg dl-1) by sampling















Figure 5. Serum blood urea nitrogen (BUN) levels (mg dl-1) by
sampling day, for ractopamine-treated (25 to 80 days of preg-
















Figure 6. Serum total protein (TP) levels (g dl-1) by sampling
day, for ractopamine-treated (25 to 80 days of pregnancy) and
untreated sows.
Choi et al. (1992), who worked with the beta-adrenergic
drug cimaterol and did not see improvements in the
activity and diameter of mammary gland cells in rats.
Total cholesterol and triglyceride levels were
increased in ractopamine-treated sows, probably
because of the lipolytic effect of the drug. This also
resulted in increased HDL levels, since these molecules
are responsible for the transport of cholesterol from
the adipose tissue to the liver (Lehninger et al., 1993).
Blood urea nitrogen levels remained unchanged
(P > 0.05) among treatments.
Creatinine is a product of muscle contraction, and
its synthesis is increased in more active animals. The
results obtained in this trial did not reveal significant
differences (P > 0.05) among treatments. This indicates
that beta-adrenergic drugs have a negligible action on
muscle contraction, even when the drug is from the
same family as adrenaline and noradrenaline (Marsden
and Meadows, 1970; Bülbring, 1976, cited by Ingram
and Dauncey, 1986).
The serum lipid data showed that ractopamine-
treated sows presented different levels of compounds
related to lipid metabolism. This difference was caused
by the action of the drug on the lipid metabolism,
through the stimulation of the adenyl cyclase system
that promotes cAMP production, increasing the
activation of kinases which are responsible for the
phosphorylation and modification of the activities of
several enzymes, modulating metabolic processes such
as muscular contraction, lipolysis and glycogenolysis.
Although BUN levels were similar for both treat-
ments up to 60 days of pregnancy, a difference was
noted at 80 days of pregnancy when the treated group
was compared with the controls indicating a lower
protein catabolism during the stage of secondary fiber
hyperplasia. This occurrence could improve muscular
development.
The total protein values were very close for both
groups, probably because the test method used measures
total serum protein levels, regardless of the source and
use of the protein.
According to the results obtained in this trial, it can
be concluded that the 20 ppm dose of ractopamine had
no effect on reproduction, independently of the treatment
period. As for the biochemical parameters, some were
changed as a result of the action of the drug on lipid
and protein metabolism.
In conclusion, the use of ractopamine at 20 ppm
during the pregnancy stages studied did not affect the
number of piglets born or the birth or weaning weights.
The lipid profile of ractopamine-treated pregnant sows
was changed, with elevation of total cholesterol,
triglyceride and HDL values, when compared to the
control group (71.80 mg dl-1 vs 65.04 mg dl-1; 42.30
mg dl-1 vs 37.00 mg dl-1, and 59.40 mg dl-1 vs 53.40 mg
dl-1, respectively). Immune cells or blood values were
not affected in ractopamine-treated pregnant sows.
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